Corcept.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD, and by chief medical officer Robert S. Fishman, MD. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and non-alcoholic steatohepatitis (NASH). In February 2012, the company introduced Korlym ® , the first medication approved by the U.S. Food and Drug Administration for the treatment of …WebAbout Corcept. Executive Team. Board of Directors. Educational Grants. Contact Us. Meet the Corcept Therapeutics executive team to find out more about their background and experience in the biopharmaceutical industry.MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program. Corcept will present results from the company’s 178-patient, randomized, controlled, …

Corcept Therapeutics is engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept’s first approved product, Korlym, inhibits the effects of excess cortisol in patients with hypercortisolism by modulating ...Jul 26, 2023

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

View Our Latest Research Report on CORT. Corcept Therapeutics Stock Up 2.0 %. CORT opened at $25.97 on Friday. The firm has a market cap of $2.68 billion, a PE ratio of 32.06 and a beta of 0.43.CORCEPT THERAPEUTICS INC. share price in real-time (529882 / US2183521028), charts and analyses, news, key data, turnovers, company data.Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...About Corcept’s Ovarian Cancer Program. The data in this release come from Corcept’s 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. 5 The women who entered the trial had experienced disease progression on prior lines of therapy. The median ...About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...

Corcept Celebrates Hispanic Trailblazers During this Hispanic Heritage Month, we honor Dr. Bernardo Alberto Houssay (1887-1971), one of three Argentinians to receive the Nobel Prize in physiology ...

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, ...

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking StatementsCorcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis ...WebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Feb 28, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis ...Web

Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side. The tablets are not scored. 4 CONTRAINDICATIONS KORLYM is contraindicated in: • Pregnancy [See Dosage and Administration (2.1), Use in Specific Populations (8.1,8.3)]Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 …MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program. Corcept will present results from the company’s 178-patient, randomized, controlled, …--Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by ...MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users …WebMENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking Statements.Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...WebMar 6, 2023 · Corcept may not consummate the tender offer described in this press release and, if the tender offer is consummated, cannot provide any assurances regarding the final terms of the tender offer. Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as diabetes, cancer, and depression.For more information, go to www.korlym.com or www.corcept.com or call 1-855-456-7596. This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 11/2019 2. Created Date:Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWebCorcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.Corcept’s second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021. Second quarter operating expenses were $72.0 million , compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and ...WebCorcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements.

On November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and …Web

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to ...Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ...Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state.Jun 30, 2021 · Corcept holds patents covering the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism. About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders ... About Corcept. Executive Team. Board of Directors. Educational Grants. Contact Us. 149 Commonwealth Drive, Menlo Park, CA 94025. Phone: 650-327-3270. Email: [email protected]. Contact us with questions about Corcept, for more information about the company, or where we are located. Nov 2, 2023 · We are raising our 2023 revenue guidance again to a range of $470 million to $480 million, up from $455 million to $470 million. Net income was $31.4 million or $0.28 per share in the third ... Feb 28, 2023 · Corcept Therapeutics Q1 2021 Earnings Conference Call. Feb 8, 2021 at 5:00 PM EST. Corcept Therapeutics (Menlo Park, California, USA) funded the Consensus Advisory Board; discussion during this event contributed to these consensus recommendations. Corcept Therapeutics also funded the preparation of this manuscript for publication, including medical writing and editorial assistance, and the Open Access Fee. ...WebCorcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWebDec 8, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

Mar 31, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ... study CORT125134-451 (NCT02804750) are supported by Corcept Therapeutics. Editorial support was provided by Tina K. Schlafly of Corcept Therapeutics. Funding for design and production support for this poster was provided by Corcept to MedVal Scientific Information Services (Princeton, NJ). TheData from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021; Results show statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary selective cortisol modulator, relacorilantManagement and especially upper management has created a culture of produce or you are gone. Great for the person who produces but hit the skids ...Instagram:https://instagram. sell my xbox 360best home loan lenders for self employedmaterials sector stockswes price Corcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million , compared to $69.8 million in the third quarter of 2022, due to increased clinical … military dental insurance costd z z Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...WebCorcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has …Web home depot same day delivery The Associate Director, Clinical Operations will provide expertise and oversight for multiple clinical trials or a clinical program to ensure the trials are conducted in accordance with the protocols, SOPs, GCP and departmental and corporate goals. This role will provide leadership and direction to the Clinical Operations teams in the ...Corcept conducted the drug-drug interaction study de-scribed in Lee, collecting data on co-administration of mif-epristone with a strong CYP3A inhibitor. Based on that data, Corcept sought and received the ’214 patent . The ’214 patent relates to methods of treating Cushing’s syndrome by co-administering mifepristone and a strong CYP3A in-